ArQule, Inc.  

(Public, NASDAQ:ARQL)   Watch this stock  
Find more results for ARQL
1.00
-0.01 (-0.99%)
Apr 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.00 - 1.03
52 week 0.92 - 2.17
Open 1.00
Vol / Avg. 0.00/165,711.00
Mkt cap 70.45M
P/E     -
Div/yield     -
EPS -0.33
Shares 71.15M
Beta 1.50
Inst. own 60%
May 23, 2017
ArQule Inc Annual Shareholders Meeting - 10:00AM EDT - Add to calendar
May 3, 2017
Q1 2017 ArQule Inc Earnings Release - 9:30AM EDT - Add to calendar
May 3, 2017
Q1 2017 ArQule Inc Earnings Call - 9:00AM EDT - Add to calendar
Apr 4, 2017
ArQule Inc at Needham Healthcare Conference - Webcast
Mar 7, 2017
Q4 2016 ArQule Inc Earnings Release
Mar 7, 2017
Q4 2016 ArQule Inc Earnings Call
Feb 17, 2017
ArQule Inc and Daiichi Sankyo to Announce the Completion of the METIV-HCC Phase 3 Study of Tivantinib in Hepatocellular Carcinoma
Feb 15, 2017
ArQule Inc at Leerink Partners Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -574.56% -482.44%
Operating margin -578.18% -486.22%
EBITD margin - -484.07%
Return on average assets -77.15% -62.77%
Return on average equity -101.77% -85.96%
Employees 36 -
CDP Score - -

Address

1 Wall St
BURLINGTON, MA 01803-4769
United States - Map
+1-781-9940300 (Phone)
+1-781-3766019 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ArQule, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations. The Company's lead product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase (MET) and its biological pathway. The Company's product candidates include ARQ 092, designed to inhibit the AKT serine/threonine kinase; ARQ 087, a multi-kinase inhibitor designed to inhibit the fibroblast growth factor receptor (FGFR) family, and ARQ 761, a Beta lapachone analog being evaluated in investigator-sponsored testing as a promoter of NQO1-mediated programmed cancer cell necrosis.

Officers and directors

Patrick J. Zenner Independent Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Peter S. Lawrence President, Chief Operating Officer
Age: 52
Bio & Compensation  - Reuters
Paolo Pucci Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Robert J. Weiskopf Chief Financial Officer, Treasurer
Age: 62
Bio & Compensation  - Reuters
Brian Schwartz M.D. Chief Medical Officer
Age: 53
Bio & Compensation  - Reuters
Timothy C. Barabe Independent Director
Age: 63
Bio & Compensation  - Reuters
Susan L. Kelley M.D. Independent Director
Age: 61
Bio & Compensation  - Reuters
Ronald M. Lindsay Ph.D. Independent Director
Age: 67
Bio & Compensation  - Reuters
Michael D. Loberg Ph.D. Independent Director
Age: 67
Bio & Compensation  - Reuters
William G. Messenger D. Min. Independent Director
Age: 54
Bio & Compensation  - Reuters